Page last updated: 2024-09-05

sch 58261 and 2-hexynyladenosine-5'-n-ethylcarboxamide

sch 58261 has been researched along with 2-hexynyladenosine-5'-n-ethylcarboxamide in 2 studies

Compound Research Comparison

Studies (sch 58261)	Trials (sch 58261)	Recent Studies (post-2010) (sch 58261)	Studies (2-hexynyladenosine-5'-n-ethylcarboxamide)	Trials (2-hexynyladenosine-5'-n-ethylcarboxamide)	Recent Studies (post-2010) (2-hexynyladenosine-5'-n-ethylcarboxamide)
46	0	14	28	0	2

Protein Interaction Comparison

Protein	Taxonomy	sch 58261 (IC50)	2-hexynyladenosine-5'-n-ethylcarboxamide (IC50)
Adenosine receptor A1	Rattus norvegicus (Norway rat)		4.38

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arslan, G; Dionisotti, S; Fredholm, BB; Kull, B; Ongini, E; Zocchi, C	1
Arslan, G; Fredholm, BB; Kull, B; Lorenzen, A; Nilsson, C; Owman, C; Schwabe, U	1

Other Studies

2 other study(ies) available for sch 58261 and 2-hexynyladenosine-5'-n-ethylcarboxamide

Article	Year
Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. British journal of pharmacology, 1997, Volume: 121, Issue:3 Topics: Animals; Binding, Competitive; CHO Cells; Cricetinae; Cyclic AMP; Humans; Purinergic P1 Receptor Antagonists; Pyrimidines; Radioligand Assay; Rats; Receptor, Adenosine A2A; Receptors, Purinergic P1; Species Specificity; Transfection; Triazoles	1997
Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochemical pharmacology, 1999, Jan-01, Volume: 57, Issue:1 Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Binding, Competitive; CHO Cells; Cloning, Molecular; Cricetinae; Cyclic AMP; Humans; Kinetics; PC12 Cells; Phenethylamines; Polymerase Chain Reaction; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Pyrimidines; Radioligand Assay; Rats; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptors, Purinergic P1; Recombinant Proteins; RNA, Messenger; Transcription, Genetic; Transfection; Triazoles; Tritium	1999

Article

Year

Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.

British journal of pharmacology, 1997, Volume: 121, Issue:3

Topics: Animals; Binding, Competitive; CHO Cells; Cricetinae; Cyclic AMP; Humans; Purinergic P1 Receptor Antagonists; Pyrimidines; Radioligand Assay; Rats; Receptor, Adenosine A2A; Receptors, Purinergic P1; Species Specificity; Transfection; Triazoles

1997

Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors.

Biochemical pharmacology, 1999, Jan-01, Volume: 57, Issue:1

Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Binding, Competitive; CHO Cells; Cloning, Molecular; Cricetinae; Cyclic AMP; Humans; Kinetics; PC12 Cells; Phenethylamines; Polymerase Chain Reaction; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Pyrimidines; Radioligand Assay; Rats; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptors, Purinergic P1; Recombinant Proteins; RNA, Messenger; Transcription, Genetic; Transfection; Triazoles; Tritium

1999